BioNTech SE (NASDAQ:BNTX) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG raised its stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) by 2.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,500 shares of the company's stock after purchasing an additional 6,749 shares during the quarter. Deutsche Bank AG owned about 0.13% of BioNTech worth $34,698,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of BioNTech by 22.2% in the fourth quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of BioNTech in the fourth quarter worth $69,999,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of BioNTech by 632.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after purchasing an additional 433,388 shares during the last quarter. Capital International Investors lifted its holdings in shares of BioNTech by 38.6% during the fourth quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after acquiring an additional 394,434 shares during the period. Finally, abrdn plc grew its holdings in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after acquiring an additional 159,676 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Up 3.3%

Shares of BNTX traded up $3.05 on Monday, reaching $95.82. The stock had a trading volume of 282,619 shares, compared to its average volume of 930,091. The firm has a market capitalization of $23.03 billion, a price-to-earnings ratio of -45.72 and a beta of 1.35. The company has a 50-day simple moving average of $97.41 and a 200-day simple moving average of $108.81. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's quarterly revenue was down 19.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.90 earnings per share. Sell-side analysts predict that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on BNTX shares. HC Wainwright reissued a "buy" rating and set a $134.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Wednesday. Citigroup reissued a "buy" rating and issued a $140.00 price objective (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Morgan Stanley cut their price objective on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $142.08.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.